RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED OR REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
MRNA therapy takes on Hard-to-Treat multiple myeloma
Disease control Recruiting nowThis study tests a new drug called mRNA-2808 in people with multiple myeloma that has returned or not responded to standard treatments. The drug is given through a vein and aims to control the cancer. The trial will check for side effects and measure how well the drug works. Abou…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New cocktail of cancer drugs aims to outsmart relapsed myeloma
Disease control Recruiting nowThis umbrella trial tests the drug isatuximab (Sarclisa) combined with several newer agents, with or without dexamethasone, in adults whose multiple myeloma has returned or stopped responding to at least two prior treatments. About 258 participants will be assigned to different s…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for myeloma: phase 3 trial launches for mezigdomide combo
Disease control Recruiting nowThis Phase 3 trial is testing whether a new drug called mezigdomide, combined with two standard drugs (bortezomib and dexamethasone), works better than the current standard combination (pomalidomide, bortezomib, and dexamethasone) for people with multiple myeloma that has come ba…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for hard-to-treat blood cancer: combo therapy trial launches
Disease control Recruiting nowThis study tests several combinations of the experimental drug QLS32015 with other medicines in 160 people whose multiple myeloma has come back or stopped responding to prior therapy. The goal is to see which combination works best to shrink tumors and achieve deep remission. Par…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New Triple-Action antibody targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called JNJ-79635322, a trispecific antibody designed to attack cancer cells in people with relapsed or refractory multiple myeloma or AL amyloidosis. About 180 participants will receive the drug to find a safe dose and check for s…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo aims to tackle Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage trial is testing whether combining two drugs, cevostamab and elranatamab, is safe and tolerable for people with multiple myeloma that has returned or not responded to prior treatments. About 120 participants will receive the drugs, and researchers will monitor si…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental cancer therapy targets Tough-to-Treat myeloma
Disease control Recruiting nowThis early-stage trial is testing a new treatment called KSVCBD for people with multiple myeloma that has come back or not responded to at least three prior treatments. KSVCBD is a type of CAR-T cell therapy given directly into the body to target two proteins (CD19 and BCMA) on m…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for Hard-to-Treat myeloma: QLS32015 enters phase 3 trial
Disease control Recruiting nowThis study tests a new drug called QLS32015 against two standard treatment combinations (pomalidomide with dexamethasone or selinexor with dexamethasone) in 228 people with multiple myeloma that has relapsed or is refractory. The main goal is to see if QLS32015 can delay cancer p…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New hope for myeloma: experimental drug takes on standard combo
Disease control Recruiting nowThis phase 3 trial is testing a new drug called GR1803 against a standard three-drug combination (daratumumab, pomalidomide, and dexamethasone) in people with multiple myeloma that has come back after 1 to 3 prior treatments. About 358 participants will be randomly assigned to re…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New Tri-Specific antibody takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage trial tests a new drug called SIM0500 in 130 adults with multiple myeloma that has returned or stopped responding to treatment. SIM0500 is a tri-specific antibody designed to help the immune system attack cancer cells. The study will first find the safest dose, t…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New bispecific antibody YKST02 enters human trials for Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase study is testing a new drug called YKST02 in 70 people with multiple myeloma that has relapsed or not responded to at least two prior treatments. YKST02 is a bispecific antibody designed to attach to both myeloma cells and immune cells, helping the immune system …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New Dual-Targeting CAR t therapy takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage trial tests a new cell therapy called O&D-001 for people with multiple myeloma that has come back or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to attack two cancer targets (BCMA and GPRC5D). The study will enroll 18 …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: O&D BioTech Group CO., Limited • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for hard-to-treat myeloma: experimental combo tested in phase 2 trial
Disease control Recruiting nowThis study tests a new drug called F182112 given with different treatment plans for people whose multiple myeloma has returned or stopped responding to prior therapies. About 90 participants will receive the drug combination to see if it shrinks tumors and how safe it is. The goa…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC